The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...
Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is “the ...
The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan ...
Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, ...
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year.
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while ...
A renewal of the FDA’s pediatric rare disease voucher program is couched within a massive $1.2 trillion spending bill the ...
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback